Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels and higher test volumes. The latest version of QCI Interpret introduces ...

Venlo, the Netherlands, June 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today released its 2023 Sustainability Report which underscores the company's commitment to Environmental, Social, and Governance (ESG) principles, highlighting substantial achievements in its sustainability journey. "In line with our vision of making improvements in life possible, we are committed to delivering the best possible portfolio of products and services while leaving the smallest possible ...

Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmit ...

QIAGEN N.V. (QGEN) recently launched the digital PCR (polymerase chain reaction) Custom Assay Design Tool for copy number variation (CNV) analysis for use on the QIAcuity digital PCR (dPCR) platform. Alongside this, the company announced several other enhancements in its GeneGlobe Design and Analysis Hub — a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities, including genes, miRNAs and pathways. The latest developments aim to support ...

Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems. This decision will allow QIAGEN to refocus resources and efforts on developing and commercializing other innovative solutions within ...

Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems. This decision will allow QIAGEN to refocus resources and efforts on developing and commercializing other innovative solutions within ...

Venlo, the Netherlands, June 05, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathway ...

QIAGEN N.V. (QGEN) announced the launch of QIAstat-Dx Gastrointestinal Panel 2 in the United States following the recent FDA clearance of the syndromic test for use in clinical settings. The launch marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis. The latest development from QIAGEN addresses the major challenges of the diagnosis of overlapping symptoms and laborious testing methods in treating GI infections. This should also strengthen th ...

QIAGEN N.V. (QGEN) recently announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid capture from a single sample. The latest development is likely to enhance QIAGEN’s Life Sciences business area. The kit adds to the company’s growing portfolio that harnesses the tr ...

Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration (FDA) and marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis. The QIAstat-Dx Gastrointestinal ...